You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Serum free IgE guided dose reduction of omalizumab: a case report
|
|---|---|
| Published in |
Allergy, Asthma & Clinical Immunology, August 2017
|
| DOI | 10.1186/s13223-017-0211-z |
| Pubmed ID | |
| Authors |
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto |
| Abstract |
Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for severe asthma patients who are allergic to perennial allergens. The effects of omalizumab for severe asthma therapy have been validated in multiple clinical studies. However, the long-term effects of omalizumab on IgE production and possibility of resetting of administration dose of omalizumab remain unknown. The serum total and free IgE levels were measured over time in a 63-year-old female patient with allergic asthma who was administered 375 mg omalizumab biweekly for 36 months. Her symptoms did not worsen and clinical course remained favorable after reducing the dose to 375 mg per month. The serum free IgE levels temporarily increased following a dose reduction of omalizumab. The serum free IgE trough level temporarily increased at 4 weeks after capable to reduce the dosage; however, thereafter, the serum free IgE level decreased to desired levels (below 30 ng/mL). The present case shows the possibility of reducing the dose following the long-term use of omalizumab. Considering the high medical cost of omalizumab, the dose reduction may be a viable option. It may be useful to measure the serum free IgE level to appropriately identify patients in whom the dose can be reduced, and to carefully monitor the clinical course. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 16% |
| Student > Ph. D. Student | 2 | 11% |
| Researcher | 2 | 11% |
| Student > Master | 2 | 11% |
| Student > Bachelor | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 8 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 26% |
| Biochemistry, Genetics and Molecular Biology | 3 | 16% |
| Immunology and Microbiology | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 7 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2017.
All research outputs
#3,275,949
of 25,382,440 outputs
Outputs from Allergy, Asthma & Clinical Immunology
#216
of 924 outputs
Outputs of similar age
#57,179
of 323,945 outputs
Outputs of similar age from Allergy, Asthma & Clinical Immunology
#3
of 12 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 924 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.8. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,945 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.